Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Ariad Pharmaceuticals
Ariad Pharmaceuticals
Takeda touts positive first-line leukemia results — but isn't quite ready to reveal the hard data
Takeda touts positive first-line leukemia results — but isn't quite ready to reveal the hard data
Endpoints
Takeda
Ariad Pharmaceuticals
Iclusig
clinical trials
acute lymphoblastic leukemia
Flag link:
OrbiMed-incubated Theseus unveils $100M to beat cancer drug resistance
OrbiMed-incubated Theseus unveils $100M to beat cancer drug resistance
MedCity News
OrbiMed
Ariad Pharmaceuticals
Theseus Pharmaceuticals
cancer
Flag link:
'Burner' phones and Ariad secrets: Goldman Sachs banker pleads guilty for his role in global insider trading ring
'Burner' phones and Ariad secrets: Goldman Sachs banker pleads guilty for his role in global insider trading ring
Endpoints
insider trading
Goldman Sachs
Ariad Pharmaceuticals
Flag link:
Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years
Drug Approvals for the 2 Most Common Types of Cancer in the Last 2 Years
BioSpace
cancer
breast cancer
lung cancer
drug approvals
AstraZeneca
Takeda
Ariad Pharmaceuticals
Merck
Pfizer
Novartis
Boehringer Ingelheim
Bristol-Myers Squibb
Eli Lilly
Puma Biotechnology
Mylan
Genentech
Flag link:
Why Has 2017 Been a Horrible Year So Far for Biotech Acquisitions?
Why Has 2017 Been a Horrible Year So Far for Biotech Acquisitions?
Motley Fool
biotech
M&A
JNJ
Actelion
Takeda
Ariad Pharmaceuticals
Gilead Sciences
Pfizer
Amgen
Flag link:
Takeda's Ariad deal pays off with blockbuster green light for Alunbrig
Takeda's Ariad deal pays off with blockbuster green light for Alunbrig
Fierce Pharma
Takeda
Ariad Pharmaceuticals
Alunbrig
ALK-positive non-small cell lung cancer
Flag link:
About that pharma M&A comeback? Sorry. 2017's not bringing it—at least not yet
About that pharma M&A comeback? Sorry. 2017's not bringing it—at least not yet
Fierce Pharma
M&A
Stada
Shire
Baxalta
JNJ
Actelion
Mylan Labs
Pfizer
Takeda
Ariad Pharmaceuticals
Medivation
Flag link:
Takeda chops into Ariad staff, handing out about 180 pink slips as it revamps Boston ops
Takeda chops into Ariad staff, handing out about 180 pink slips as it revamps Boston ops
Endpoints
Takeda
layoffs
Ariad Pharmaceuticals
reorganization
Flag link:
How Takeda won a $5.2B bidding war — against itself
How Takeda won a $5.2B bidding war — against itself
Endpoints
Takeda
M&A
Ariad Pharmaceuticals
Flag link:
Takeda deal results in a huge windfall for former Ariad CEO Harvey Berger
Takeda deal results in a huge windfall for former Ariad CEO Harvey Berger
Bizjournals.com
Takeda
Ariad Pharmaceuticals
Harvey Berger
Flag link:
Takeda Pharmaceutical to buy Ariad in $5.2 billion cash deal
Takeda Pharmaceutical to buy Ariad in $5.2 billion cash deal
Yahoo/AP
Takeda
Ariad Pharmaceuticals
M&A
Flag link:
3 Big Advances In Cancer Treatment In 2016
3 Big Advances In Cancer Treatment In 2016
Motley Fool
cancer
Merck
Keytruda
Kite Pharma
KTE-C19
Ariad Pharmaceuticals
brigatinib
Flag link:
Bernie Sanders Follows ‘Greed’ Tweet on Ariad With Letter
Bernie Sanders Follows ‘Greed’ Tweet on Ariad With Letter
Bloomberg
Bernie Sanders
twitter
Ariad Pharmaceuticals
Iclusig
drug pricing
Flag link:
3 Cancer Drugs That Could Get an FDA OK Next Year
3 Cancer Drugs That Could Get an FDA OK Next Year
Motley Fool
FDA
rucaparib
Clovis Oncology
ovarian cancer
binimetinib
Array Biopharma
melanoma
brigatinib
Ariad Pharmaceuticals
non-small cell lung cancer
Flag link:
Ariad Shares Rise Amid Speculation of Potential Buyout
Ariad Shares Rise Amid Speculation of Potential Buyout
Bloomberg
Ariad Pharmaceuticals
M&A
Flag link:
Ariad Taking The Fast Track Into Lung Cancer Treatment
Ariad Taking The Fast Track Into Lung Cancer Treatment
Seeking Alpha
Ariad Pharmaceuticals
fast track
non-small cell lung cancer
Ponatinib
Flag link:
Here are 13 MA cancer biotechs hoping to make waves next month
Here are 13 MA cancer biotechs hoping to make waves next month
Bizjournals.com
Boston
biotech
ASCO 2016
Ariad Pharmaceuticals
Immunogen
Ziopharm
Vertex Pharmaceuticals
Tokai
Infinity Pharmaceuticals
Momenta
Merrimack
Tesaro
Syndax
Kyropharm
Foundation Medicine
Cerulean Pharma
Flag link:
Ariad Pharmaceuticals Takes An Axe To Its Expenses
Ariad Pharmaceuticals Takes An Axe To Its Expenses
Motley Fool
Ariad Pharmaceuticals
layoffs
Flag link:
Ariad Pharmaceuticals reports fourth-quarter loss, misses expectations
Ariad Pharmaceuticals reports fourth-quarter loss, misses expectations
Yahoo/AP
Ariad Pharmaceuticals
earnings
Flag link:
Why Ariad Pharmaceuticals Flew in August (Hint: It Wasn't Because of Red Bull)
Why Ariad Pharmaceuticals Flew in August (Hint: It Wasn't Because of Red Bull)
Motley Fool
Ariad Pharmaceuticals
Baxalta
M&A
Flag link:
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »